Drug profile · INN
patisiran sodium
ONPATTRO
patisiran sodium (ONPATTRO) is a transthyretin mrna rnai inhibitor. Associated with Alnylam Netherlands B.V.. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — patisiran sodium
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 20
- Programs
- 7
- Data quality
- 0.89
Quick answer
patisiran sodium (ONPATTRO) is a transthyretin mrna rnai inhibitor. Associated with Alnylam Netherlands B.V.. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Transthyretin mRNA RNAi inhibitor
Primary target: Transthyretin mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12416006
Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof
granted -
US 12404508
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
granted -
US 12397013
Extrahepatic delivery
granted -
US 12364762
Biodegradable lipids for the delivery of active agents
granted -
US 12350338
Biodegradable lipids for the delivery of active agents
granted -
US 12343398
Biodegradable lipids for the delivery of active agents
granted -
US 12331297
Coagulation factor V (F5) iRNA compositions and methods of use thereof
granted -
US 12241064
REVERSIR™ compounds
granted -
US 12239709
Biodegradable lipids for the delivery of active agents
granted -
US 12227744
Compositions and methods for inhibiting expression of transthyretin
granted -
US 12173288
Oligonucleotide-ligand conjugates and process for their preparation
granted -
US 12173289
Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
granted -
US 12071619
SERPINA1 iRNA compositions and methods of use thereof
granted -
US 12059468
Carbohydrate conjugates as delivery agents for oligonucleotides
granted -
US 12049630
Factor XII (F12) iRNA compositions and methods of use thereof
granted -
US 12018260
Tunable Reversir™ compounds
granted -
US 12005074
Extrahepatic delivery
granted -
US 11987792
Compositions and methods for inhibiting expression of the LECT2 gene
granted -
US 11965166
Complement factor B (CFB) iRNA compositions and methods of use thereof
granted -
US 11959081
Transthyretin (TTR) iRNA compositions and methods of use thereof
granted
Frequently asked questions
What is patisiran sodium?
patisiran sodium (ONPATTRO) is a transthyretin mrna rnai inhibitor. Associated with Alnylam Netherlands B.V.. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for patisiran sodium?
ONPATTRO is a marketed brand name for patisiran sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of patisiran sodium?
patisiran sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.